Quick answers
- What is Iobenguane I-123 used for?
- The FDA-approved label (AdreView, Medi-Physics Inc., January 10, 2024) says: “AdreView is a radiopharmaceutical agent for gamma-scintigraphy indicated for: use in the detection of primary or metastatic pheochromocytoma or neuroblastoma as an adjunct to other diagnostic tests scintigraphic assessment of sympathetic innervation of the myocardium by measurement of the heart to mediastinum (H/M) ratio of radioactivity uptake in patients with New York Heart Association (NYHA) class II or class III …” This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
- Does Iobenguane I-123 have a boxed warning?
- No. None of the 1 FDA labels we found for this medicine has a boxed warning.
- Is there a shortage of Iobenguane I-123?
- No current shortage is listed by the FDA for the products of this medicine (FDA data from October 30, 2026).
- Has Iobenguane I-123 been recalled?
- No recall linked to the products of this medicine appears in the FDA enforcement reports we use.
- Who makes Iobenguane I-123?
- 1 company lists prescription products of Iobenguane I-123 in the FDA NDC Directory, including Medi-Physics Inc..
What Iobenguane I-123 is used for
Quoted from the “Indications and Usage” section of the FDA-approved label.
AdreView is a radiopharmaceutical agent for gamma-scintigraphy indicated for: use in the detection of primary or metastatic pheochromocytoma or neuroblastoma as an adjunct to other diagnostic tests scintigraphic assessment of sympathetic innervation of the myocardium by measurement of the heart to mediastinum (H/M) ratio of radioactivity uptake in patients with New York Heart Association (NYHA) class II or class III …
— FDA label: AdreView, Medi-Physics Inc., effective January 10, 2024. Read the full label on DailyMed →
This page is not medical advice. Talk to your doctor or pharmacist before you start, stop or change any medicine.
Conditions named on the label
These condition names appear word for word in the label’s “Indications and Usage” text (matched with a reviewed table). Each page lists hospitals whose own websites name the condition.
Related medical specialties
Boxed warning
A boxed warning (“black box”) is the FDA’s strongest warning on a drug label, for serious or life-threatening risks.
The label quoted above has no boxed warning.
Forms and how it is given
| Dosage forms | Injection |
|---|---|
| Route | Intravenous |
| Prescription products | 1 in the FDA NDC Directory |
| Brand names | Adreview |
Companies that list this medicine
Labelers in the FDA NDC Directory: the company named on the package (maker or distributor), with the number of prescription products.
- Medi-Physics Inc.1 product
FDA approval history
- NDA: New Drug Application: how a new (usually brand-name) medicine is approved.
| Application | Sponsor | Approved | Later changes approved |
|---|---|---|---|
| NDA022290 ADREVIEW | Ge Healthcare | September 19, 2008 | 3, latest March 5, 2020 2020: Labeling · 2016: Manufacturing (CMC) · 2013: Efficacy |
Shortage status
The FDA drug shortage list does not show these products.
Recalls
No recall linked to these products (by their NDC code) appears in the FDA enforcement reports.
Official identifiers
| SPL set ID of the quoted label | c89d3ecc-4f4c-4566-8808-79152344194d |
|---|---|
| FDA labels (SPL) | 1 |
| FDA applications | NDA022290 |
| Active ingredients (FDA) | IOBENGUANE I-123 |
Sources
- FDA-approved label on DailyMed (National Library of Medicine) — AdreView, Medi-Physics Inc., effective January 10, 2024; via openFDA, FDA data exported October 30, 2026, retrieved October 31, 2026
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- Drug shortages (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
openFDA data is provided by the FDA as is; it may be incomplete. Always rely on the label that comes with your medicine. FDA Enforcement Report search →